Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-09-17 16:15:14 ET · period of report 2026-09-16 · accession 0002048497-26-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-17 16:15 | 2026-09-16 | BBNX | Hopman Mark | Chief Commercial Off | S - Sale | $20.13 | -30.8K | 56.5K | -35% | -$619.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-16 | S | D | 30,779 | $20.13 | 56,479 | D | — | — | (F1) Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026. (F2) The weighted average sale price for the transaction reported was $20.1319 and the range of prices were between $20.00 and $20.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |